Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
Panelists discuss how a patient who is neutropenic is given supportive care with GCSF, as do patients who have prolonged neutropenia, then that patient will be on antibiotic and antifungal prophylaxis.
EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy
EP: 2.Role of Step-Up Dosing
EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy
EP: 4.Strategies For Management of Infections
EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients
EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy
EP: 7.Patient Tolerability of Talquetamab and Use of IVIG
Now Viewing
EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy
EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific
EP: 10.Dosing Strategies in Different Targets Bispecifics
EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel
Video content above is prompted by the following:
- Given the patient’s history of frequent infections, how would you balance talquetamab’s efficacy with the need for infection control, and what supportive measures might you prioritize?
- How would you approach treatment sequencing if the patient progresses on talquetamab, and what criteria would you use to determine the next line of therapy?
Recent Videos
Related Content
